Tamoxifen

Tamoxifen (TAM) is a selective estrogen receptor modulator primarily used in the management of breast cancer, acting on estrogen receptors found in various tissues, including the breast and retina. Researchers primarily study tamoxifen for its role in treating estrogen-receptor positive breast cancer and understanding the mechanisms behind its resistance. Key findings indicate that tamoxifen resistance can be linked to factors such as dysregulated mitochondrial dynamics and the upregulation of proteins like RelB and GPX4, which inhibit cell death pathways. Additionally, clinical evidence suggests that tamoxifen may lead to rare side effects, including thrombocytopenia and retinopathy, highlighting the need for ongoing monitoring. Current research continues to explore the optimal use of tamoxifen and its comparative effectiveness against newer therapies, underscoring its enduring relevance in breast cancer treatment.

Tamoxifen, also known as Nolvadex, TAM, or SERM, is a synthetic selective estrogen receptor modulator (SERM) primarily used in the management of breast cancer. It is not an endogenous hormone but a chemically synthesized compound. Tamoxifen belongs to the class of nonsteroidal anti-estrogens and is produced for therapeutic purposes. Researchers have extensively studied its effects on estrogen receptors, which are present in various tissues, including breast tissue and the retina. The primary physiological role of tamoxifen is in the treatment and prevention of estrogen receptor-positive breast cancer. It is also used in ductal carcinoma in situ and as a chemopreventive agent in high-risk populations. Researchers have observed its effects on retinal tissues, where it can cause retinopathy, and its influence on mitochondrial dynamics in cancer cells. Tamoxifen acts by competitively inhibiting estrogen receptors, thereby blocking the proliferative action of estrogen on mammary epithelium. It also affects mitochondrial function by modulating reactive oxygen species (ROS) levels and ferroptosis pathways, contributing to its therapeutic effects and resistance mechanisms. Pharmacokinetically, tamoxifen is well absorbed orally, but its bioavailability is subject to first-pass metabolism. It has a long half-life, allowing for daily dosing. Researchers have found that its metabolism involves cytochrome P450 enzymes, particularly CYP2D6 and CYP3A4, which convert it to active metabolites like endoxifen. Clinically, tamoxifen is widely used in the treatment of estrogen receptor-positive breast cancer in both pre- and postmenopausal women. It is approved by regulatory agencies such as the FDA, TGA, and MHRA for this purpose. Ongoing research aims to optimize its use and compare its efficacy with newer agents like aromatase inhibitors. Tamoxifen is generally well-tolerated, but it can cause side effects such as thrombocytopenia and retinopathy, which require monitoring during therapy.

Tamoxifen acts primarily on estrogen receptors, where it functions as an antagonist in breast tissue, inhibiting estrogen-mediated cellular proliferation. It also influences mitochondrial pathways by modulating reactive oxygen species levels and ferroptosis, contributing to its therapeutic and resistance profiles.

Tamoxifen (TAM) acts primarily as a selective estrogen receptor modulator (SERM) by competitively inhibiting estrogen receptors (ERα and ERβ) in estrogen-sensitive tissues, particularly in breast cancer cells, thereby blocking estrogen-mediated signaling pathways such as the estrogen receptor signaling pathway. This inhibition disrupts downstream biological processes including cell proliferation and survival, promoting apoptosis in cancer cells. Additionally, TAM's effects on mitochondrial dynamics and reactive oxygen species (ROS) levels contribute to its pharmacodynamics, although the complete mechanisms underlying TAM resistance, particularly involving factors like RelB and GPX4, are not fully understood.

Current evidence is limited regarding the long-term effects of tamoxifen on retinal health, particularly the optimal screening methods for early detection of tamoxifen-induced retinopathy. Further research is needed to clarify the mechanisms underlying tamoxifen resistance, especially the role of mitochondrial dynamics and ferroptosis, which could be explored through larger randomized controlled trials (RCTs) focusing on diverse patient populations. Additionally, the incidence and management of rare side effects, such as thrombocytopenia, require more comprehensive studies to establish causative relationships and treatment protocols.